Valuation dashboard for Azitra, Inc. (AZTR) with P/E N/A, P/B 0.41, EV/EBITDA 0.84 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.16, AZTR has negative trailing earnings (P/E not meaningful) and an ROE of -205.45%. Market capitalisation stands at $2M.
Balance sheet quality for AZTR: current ratio of 2.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.84 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.29 |
| vs Current Price | +77.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AZTR | Azitra, Inc. | $2M | 0.41 | -205.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.16 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | -205.45% |
| Return on Invested Capital | -159.45% |
| Return on Assets | -137.65% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ENVB · INDP · JSPR · LIPO · ONCO · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of AZTR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks